Endosense secures US$40.3 million series c financing to advance cardiac arrhythmias treatment with catheter ablation


Endosense, a developer of catheter ablation technology for the treatment of cardiac arrhythmias, has announced the close of a US$40.3 million series C financing.

Proceeds will be used to support the growth of a new direct sales organisation in Europe; commercialisation of the recently European introduction of the third-generation TactiCath Quartz force-sensing catheter; development of next generation products; completion of the TOCCASTAR investigational device exemption clinical study follow-up and FDA approval submission for the TactiCath; and, the launch of the device in the United States.

Led by new investor NGN Capital, the round drew large participation from all existing investors, including Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie, as well as multiple employees.

“The global market for electrophysiology and atrial fibrillation is one of the fastest growing areas in cardiovascular intervention. Endosense’s force-sensing technology is designed to shorten procedure times and deliver better outcomes and, as such, provides a major growth opportunity. With this round, our investors have indicated their confidence in our ability to continue leading and advancing the field,” said Jan Keltjens, president, CEO and Chairman of Endosense. “We are well positioned for rapid and sustained growth in Europe with our next generation TactiCath Quartz, which will be commercialised and supported by our new direct sales force, and we are enthusiastic about our prospects for expansion into the United States.”

As part of the financing activity, NGN Capital managing general partner Peter Johann, has joined the Endosense board of directors.

“Endosense’s proprietary force-sensing technology holds tremendous promise to improve standard of care in the catheter ablation treatment of cardiac arrhythmias,” said Johann. “We believe that the company’s strong leadership, deep body of clinical evidence and strategic vision for growing the field will yield significant value and deliver important benefit to electrophysiologists and patients around the world.”

In the United States, the TactiCath is an investigational device.